Roche: promising studies for faricimab
(CercleFinance.com) - Roche announced late yesterday the publication in "The Lancet" of two papers reporting results from four one-year phase III studies of faricimab as a potential treatment for wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).
All four studies - which enrolled over 3,000 people in total - met their primary endpoints, showing that people treated with faricimab, with at least one administration every four months, achieved non-inferior vision gains to those treated with aflibercept administered every two months.
To date, standard of care treatment requires eye injections once a month.
Copyright (c) 2022 CercleFinance.com. All rights reserved.